Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: S&P Capital IQ Factual Report
$150.00
Provider: Stock Traders Daily
$20.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

CryoLife Inc Receives Regulatory Approval for BioFoam in Europe


Wednesday, 5 Dec 2012 08:34am EST 

CryoLife Inc announced that it has received regulatory approval in Europe to market its BioFoam Surgical Matrix as an adjunct to hemostasis in cardiovascular surgery when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. BioFoam has previously been approved in Europe as an adjunct to hemostasis in the sealing of abdominal parenchymal tissues (liver and spleen) when cessation of bleeding by ligature or other conventional methods is ineffective or impractical. 

Company Quote

10.17
-0.04 -0.39%
22 Sep 2014